Article
E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Oncology reports - 1 Feb 2008
Miyanaga Akihiko, Gemma Akihiko, Ando Masahiro, Kosaihira Seiji, Noro Rintaro, Minegishi Yuji, Kataoka Kiyoko, Nara Michiya, Okano Tetsuya, Miyazawa Hitoshi, Tanaka Tomoaki, Yoshimura Akinobu, Kobayashi Kunihiko, Iwanami Hiroshi, Hagiwara Koichi, Tsuboi Eitaka, Kudoh Shoji
Abstract excerpt
It is known that an epidermal growth factor receptor (EGFR) gene mutation(s) is present in a percentage of non-small cell lung cancers (NSCLCs). Gefitinib, an inhibitor of the tyrosine kinase activity of EGFR, is effective on most of them. The EGFR mutation status alone cannot fully predict the r...
Topics
- Cadherins
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Phosphorylation